Merck (NYSE:MRK) shares ticked up today on third-quarter results that beat the consensus forecast. The company also announced that it projects its oral COVID-19 antiviral molnupiravir to bring in between $5 billion and $7 billion in revenue next year. MRK shares were up 4.9% at $85.55 per share in early-morning trading today. MassDevice’s MedTech 100…